Genelux Corporation (GNLX) AI Stock Analysis

Founded in 2001 and headquartered in Westlake Village, California, Genelux Corporation is a clinical-stage biopharmaceutical firm advancing oncolytic viral immunotherapies for aggressive solid tumor conditions. The company's lead product candidate is Olvi-Vec, an engineered strain of the vaccinia virus designed to destroy cancer cells and stimulate antitumor immune responses in ovarian cancer and non-small-cell lung cancer. Genelux is also developing V2ACT Immunotherapy for pancreatic cancer and V-VET1 for hematologic and solid cancers. With 25 employees, the company focuses on clinical trials and research to redefine cancer treatment paradigms.

Genelux generated revenue of $11.1M in FY2022 before dropping 98.5% to $170,000 in FY2023, followed by a 95.3% decline to $8,000 in FY2024. Revenue remained flat at $8,000 in FY2025, reflecting a 3-year revenue CAGR of -91.0% from FY2022 to FY2025. Annual net losses expanded from -$5.2M in FY2022 to -$28.3M in FY2023, -$29.9M in FY2024, and -$32.1M in FY2025. This generated a net margin of -401812.5% in FY2025 alongside an operating margin of -415175.0%. Over the trailing twelve months ending June 30, 2026, revenue stood at $8,000 with EPS of -$0.86, while latest quarterly revenue fell 95.3% year-over-year.

As of June 30, 2026, Genelux held $18.7M in cash and short-term investments and $2.4M in total debt, resulting in net cash of $16.2M. Total assets stood at $26.2M and shareholders' equity was $16.1M. The company maintained a current ratio of 2.39 and a debt-to-equity ratio of 0.15. Cash burn remained significant, with operating cash flow of -$25.3M and free cash flow of -$26.4M in FY2025. Capital expenditures totaled $1.1M in FY2025, and common share count increased 43.7% over the past 5 years.

Genelux has a market capitalization of $109.5M and an enterprise value of $97.3M. The stock trades at a price-to-book multiple of 7.0x. By comparison, the median of its US-listed Healthcare peers trades at a price-to-sales multiple of 4.1x, a trailing P/E of 24.6x, and an EV-to-EBITDA multiple of 12.0x, while posting a median operating margin of 14.0%. Over the past year, GNLX shares declined 54.9%, while the S&P 500 (SPY) returned 16.8%. Year to date, the stock is down 44.5% and trades 12.0% below its 200-day average.

Wall Street coverage includes 5 Strong Buy ratings and 1 Buy rating, with 0 Hold, Sell, or Strong Sell ratings. The consensus mean price target is $18.83, representing an upside of 678.2% from the last close of $2.42. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.81 on revenue of $0. For the next fiscal year, 6 analysts project an EPS of -$0.75 and revenue of $7.8M. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is November 4, 2026.

This page is an AI-written research summary of Genelux Corporation (GNLX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GNLX income statement, GNLX balance sheet, GNLX key metrics, GNLX analyst forecast, GNLX chart. See the GNLX stock overview for the latest quote and news.